CA2098609A1 - Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence - Google Patents

Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence

Info

Publication number
CA2098609A1
CA2098609A1 CA002098609A CA2098609A CA2098609A1 CA 2098609 A1 CA2098609 A1 CA 2098609A1 CA 002098609 A CA002098609 A CA 002098609A CA 2098609 A CA2098609 A CA 2098609A CA 2098609 A1 CA2098609 A1 CA 2098609A1
Authority
CA
Canada
Prior art keywords
leu
abu
alpha
ala
cooet
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002098609A
Other languages
English (en)
Inventor
Raymond T. Bartus
David D. Eveleth, Jr.
Gary S. Lynch
James C. Powers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgia Tech Research Corp
Cortex Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2098609A1 publication Critical patent/CA2098609A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002098609A 1990-12-28 1991-12-27 Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence Abandoned CA2098609A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63595290A 1990-12-28 1990-12-28
US635,952 1990-12-28

Publications (1)

Publication Number Publication Date
CA2098609A1 true CA2098609A1 (fr) 1992-06-29

Family

ID=24549781

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002098609A Abandoned CA2098609A1 (fr) 1990-12-28 1991-12-27 Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence

Country Status (5)

Country Link
EP (1) EP0564552A1 (fr)
JP (1) JPH06504061A (fr)
AU (2) AU667463B2 (fr)
CA (1) CA2098609A1 (fr)
WO (1) WO1992011850A2 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736520A (en) * 1988-10-07 1998-04-07 Merrell Pharmaceuticals Inc. Peptidase inhibitors
EP0580161A1 (fr) * 1992-07-22 1994-01-26 THE McLEAN HOSPITAL CORPORATION Traitement prophylactique et thérapeutique de la maladie d'Alzheimer
US5371072A (en) * 1992-10-16 1994-12-06 Corvas International, Inc. Asp-Pro-Arg α-keto-amide enzyme inhibitors
US5541290A (en) * 1993-06-24 1996-07-30 Harbeson; Scott L. Optically pure calpain inhibitor compounds
US5977074A (en) * 1993-10-01 1999-11-02 Merrell Pharmaceuticals, Inc. Inhibitors of β-amyloid protein production
US5637589A (en) * 1993-10-29 1997-06-10 University Of North Carolina At Chapel Hill Suksdorfin, analogs, compositions thereof, and methods for making and using thereof
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5536639A (en) * 1994-03-25 1996-07-16 Cephalon, Inc. Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
US6319929B1 (en) 1994-04-29 2001-11-20 The University Of North Carolina At Chapel Hill Suksdorfin analogs, compositions thereof, and methods for making and using thereof
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
CA2200964A1 (fr) * 1994-11-24 1996-05-30 Takeda Chemical Industries, Ltd. Derives d'alpha-cetoamide utilises comme inhibiteurs de cathepsine l
US5691368A (en) * 1995-01-11 1997-11-25 Hoechst Marion Roussel, Inc. Substituted oxazolidine calpain and/or cathepsin B inhibitors
US5723580A (en) * 1995-09-14 1998-03-03 Cephalon, Inc. Ketomethylene group-containing aldehyde cysteine and serine protease inhibitors
US5827877A (en) * 1995-09-14 1998-10-27 Cephalon, Inc. Ketomethylene group-containing cysteine and serine protease inhibitors
ATE377006T1 (de) * 1995-11-28 2007-11-15 Cephalon Inc Aus d-aminosäuren abgeleitete cystein- und serinproteasehemmer
DE19642591A1 (de) * 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
AU4489397A (en) 1996-10-31 1998-05-22 Alcon Laboratories, Inc. The use of calpain inhibitors to treat ocular neural pathology
DE19650975A1 (de) 1996-12-09 1998-06-10 Basf Ag Neue heterocyclisch substituierte Benzamide und deren Anwendung
CN1245486A (zh) * 1996-12-11 2000-02-23 Basf公司 用作钙蛋白酶抑制剂的酮苯甲酰胺
DE69919995T2 (de) 1998-03-20 2005-09-22 Senju Pharmaceutical Co., Ltd. Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis
DE19818614A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue substituierte Amide, deren Herstellung und Anwendung
WO1999054305A1 (fr) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Amides substitues par voie heterocyclique et utilises comme inhibiteurs de calpaine
WO1999054310A2 (fr) 1998-04-20 1999-10-28 Basf Aktiengesellschaft Inhibiteurs de protease de cysteine
DE19817459A1 (de) 1998-04-20 1999-10-21 Basf Ag Neue heterozyklische substituierte Amide, Herstellung und Anwendung
ATE524440T1 (de) * 1998-05-25 2011-09-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und anwendung
IL140040A0 (en) 1998-06-03 2002-02-10 Guilford Pharm Inc N-linked sulfonamides of n-heterocyclic carboxylic acids or carboxylic acid isosteres
US6331537B1 (en) 1998-06-03 2001-12-18 Gpi Nil Holdings, Inc. Carboxylic acids and carboxylic acid isosteres of N-heterocyclic compounds
WO2000021550A2 (fr) * 1998-10-13 2000-04-20 President And Fellows Of Harvard College Methodes et compositions de traitement des maladies neurodegeneratives
US6417189B1 (en) 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
EP1244670B1 (fr) 1999-12-21 2006-03-08 MGI GP, Inc. Composes a base de derives d'hydanto ne, compositions pharmaceutiques, et modes d'utilisation
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
DK1385870T3 (da) 2000-07-21 2010-07-05 Schering Corp Peptider som inhibitorer af NS3-serinprotease fra hepatitis C-virus
KR20030081297A (ko) 2000-07-21 2003-10-17 쉐링 코포레이션 Ｃ형 간염 바이러스의 ｎｓ3-세린 프로테아제억제제로서의 신규한 펩티드
FR2817867B1 (fr) * 2000-12-11 2006-06-30 Trophos Isocoumarines inhibitrices de la production de peptide amyloide, preparation, compositions les contenant et utilisations
DE10105040A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
DE10105041A1 (de) 2001-02-05 2002-08-14 Tell Pharm Ag Hergiswil Tripeptide und Tripeptid-Derivate für die Behandlung neurodegenerativer Krankheiten
DE10105038B4 (de) 2001-02-05 2005-07-07 Neurotell Ag Tripeptid-Derivate für die Behandlung von postläsionalen Krankheiten des Nervensystems
EP1465862A1 (fr) 2002-01-17 2004-10-13 SmithKline Beecham Corporation Derives de cetoamides a substitution cycloalkyle, utiles comme inhibiteurs de cathepsine k
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
US10076384B2 (en) 2013-03-08 2018-09-18 Symple Surgical, Inc. Balloon catheter apparatus with microwave emitter
WO2016077461A2 (fr) * 2014-11-11 2016-05-19 Western University Of Health Sciences Inhibiteurs de la calpaïne spécifiques d'une isoforme, leurs procédés d'identification et leurs utilisations

Also Published As

Publication number Publication date
WO1992011850A3 (fr) 1992-09-03
AU5590596A (en) 1996-08-22
AU9152791A (en) 1992-08-17
WO1992011850A2 (fr) 1992-07-23
EP0564552A1 (fr) 1993-10-13
JPH06504061A (ja) 1994-05-12
AU667463B2 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
CA2098609A1 (fr) Utilisation d'inhibiteurs de la calpaine dans l'inhibition et le traitement de la neurodegenerescence
US5444042A (en) Method of treatment of neurodegeneration with calpain inhibitors
CA2138124A1 (fr) Utilisation d'inhibiteurs de la calpaine pour inhiber et traiter des affections medicales associees a une augmentation de l'activite de la calpaine
DE60119968T2 (de) Hepatitis c tripeptid inhibitoren
ES2323159T3 (es) Compuestos con propiedades de liberacion de la hormona del crecimiento.
JP3159806B2 (ja) トロンビン阻害剤
EP1506000B1 (fr) Sulfamides heterocycliques en tant qu'inhibiteurs du virus de l'hepatite c
KR100611540B1 (ko) 돌라스타틴 10 유도체
RU2067585C1 (ru) Производные 5-амино-4-оксигексановой кислоты и способ их получения
RU2092492C1 (ru) Производные гидразина или их соли, фармацевтическое средство, аминоалкилгидразины или их соли
JPH0789935A (ja) ファルネシル蛋白質トランスフェラーゼの複素環式抑制剤
FR2609289A1 (fr) Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
HU189531B (en) Process for producing alanin derivatives
DE10143840A1 (de) Neue Inhibitoren der Dipeptidylpeptidase I
EP0356223A2 (fr) Inhibiteurs de HIV-protéase utiles pour le traitement du SIDA
JPH11514330A (ja) ペプチドおよびペプチドアナログプロテアーゼ阻害剤
US6500802B1 (en) Peptidyl-2-amino-1-hydroxyalkanesulfonic acid cysteine protease inhibitors
US7056947B2 (en) Aza-peptide epoxides
JPS60136595A (ja) 置換エチレンジアミン誘導体、その製造方法及び該誘導体を含む医薬製剤
JP4263095B2 (ja) Ａｃｅおよびｎｅｐの両阻害剤としてのピラン誘導体
KR20000016700A (ko) 뎁시 펩티드 및 이를 유효 성분으로 하는 의약
CA2126687A1 (fr) Derives de substitution peptidyliques renfermant de l'acide phosphonique, agents antidegeneratifs
AU2005214388A1 (en) Propenoyl hydrazides
JP2002527350A (ja) 発作を治療するのに有用なアミノ酸誘導体
ES2322263T3 (es) Mitroxiderivados de enalapril y compuestos relacionados con inhibidores de ace, para el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
FZDE Dead